Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the company’s president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously
Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the companys president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously handled by the companys founder, Dr. David Goldenberg (SCAN 6/10/98). Dr. Goldenberg will resume the position of CEO, according to the company.
In other Immunomedics management moves, Philippe Barzin, general manager of Immunomedics Europe, will relocate to the companys U.S. headquarters and assume the post of vice president for global marketing and business development.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.